Disulfiram
Disulfiram (disulfiram) is a small molecule pharmaceutical. Disulfiram was first approved as Antabuse on 1982-01-01. It is used to treat alcoholism in the USA. It is known to target aldehyde dehydrogenase, mitochondrial.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| chemically-induced disorders | D064419 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Disulfiram (discontinued: Antabuse, Disulfiram)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| antabuse | ANDA | 2012-04-18 |
| disulfiram | ANDA | 2025-04-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alcoholism | EFO_0003829 | D000437 | F10.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07B: Drugs used in addictive disorders
— N07BB: Drugs used in alcohol dependence
— N07BB01: Disulfiram
P: Antiparasitic products, insecticides and repellents
— P03: Ectoparasiticides, incl. scabicides, insecticides and repellents
— P03A: Ectoparasiticides, incl. scabicides
— P03AA: Sulfur containing product ectoparasiticides
— P03AA04: Disulfiram
— P03AA54: Disulfiram, combinations
HCPCS
No data
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 2 | — | 4 | 6 | 14 |
| Cocaine-related disorders | D019970 | — | F14 | 3 | 7 | — | 1 | 1 | 11 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | 1 | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | 1 | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | 1 | — | 1 |
| Weight loss | D015431 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 4 | 6 | 1 | — | — | 8 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | 1 | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | 1 | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | — | — | 2 | 4 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 3 | — | — | 1 | 4 |
| Alcohol-related disorders | D019973 | — | F10 | 2 | 3 | — | — | — | 4 |
| Melanoma | D008545 | — | — | 2 | 2 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | 1 | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | — | — | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 2 | 1 | — | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | — | 1 | 2 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | — | — | — | — | 1 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | — | 1 |
| Retinal dystrophies | D058499 | Orphanet_71862 | — | 1 | — | — | — | — | 1 |
| Stargardt disease | D000080362 | — | H35.53 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcohol drinking | D000428 | EFO_0004329 | — | — | — | — | — | 3 | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Ankle injuries | D016512 | — | S93.4 | — | — | — | — | 1 | 1 |
| Alcoholic intoxication | D000435 | — | — | — | — | — | — | 1 | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Disulfiram |
| INN | disulfiram |
| Description | Disulfiram is an organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid. A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties. It has a role as an EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor, an angiogenesis inhibitor, an EC 3.1.1.8 (cholinesterase) inhibitor, an EC 3.1.1.1 (carboxylesterase) inhibitor, an EC 5.99.1.2 (DNA topoisomerase) inhibitor, a fungicide, an apoptosis inducer, a NF-kappaB inhibitor, an antineoplastic agent and a ferroptosis inducer. It is an organic disulfide and an organosulfur acaricide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)C(=S)SSC(=S)N(CC)CC |
Identifiers
| PDB | — |
| CAS-ID | 97-77-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL964 |
| ChEBI ID | 4659 |
| PubChem CID | 3117 |
| DrugBank | DB00822 |
| UNII ID | TR3MLJ1UAI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ALDH2
ALDH2
Organism
Homo sapiens
Gene name
ALDH2
Gene synonyms
ALDM
NCBI Gene ID
Protein name
aldehyde dehydrogenase, mitochondrial
Protein synonyms
acetaldehyde dehydrogenase 2, aldehyde dehydrogenase 2 family (mitochondrial), ALDH class 2, ALDH-E2, ALDHI, epididymis secretory sperm binding protein, liver mitochondrial ALDH, nucleus-encoded mitochondrial aldehyde dehydrogenase 2
Uniprot ID
Mouse ortholog
Aldh2 (11669)
aldehyde dehydrogenase, mitochondrial (P47738)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Disulfiram
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,866 documents
View more details
Safety
Black-box Warning
Black-box warning for: Antabuse, Disulfiram
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,113 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use